Přejít k obsahu
Merck

Přeskočit na

HTS079M

ChemiSCREEN Human VPAC2 VIP Receptor Membrane Preparation

Human VPAC2 / VIP2 GPCR membrane preparation for Radioligand binding Assays & GTPγS binding.

Přihlásit pro zobrazení organizačních a smluvních cen.

Vybrat velikost

Změnit zobrazení
Velikost baleníSkladová položkaDostupnostCena
200 units

Očekávané datum odeslání19. května 2026odAreál Kühne+Nagel spol. s r.o.

22 800,00 Kč

O této položce

UNSPSC Code:
41106514
NACRES:
NA.84
eCl@ss:
32161000

22 800,00 Kč


Očekávané datum odeslání19. května 2026podrobné informace


Technický servis
Potřebujete pomoc? Náš tým zkušených odborníků je vám k dispozici.
Dovolte nám, abychom vám pomohli


biological source

human

Quality Level

recombinant

expressed in Chem-1 cells

manufacturer/tradename

ChemiScreen, Chemicon®

technique(s)

ligand binding assay: suitable (GTPγS), radioligand binding assay (RLBA): suitable

NCBI accession no.

UniProt accession no.

shipped in

dry ice

storage temp.

-65 to -96°C

General description

Human VPAC2
Vasoactive intestinal peptide (VIP), a 28 amino acid peptide originally isolated by its vasodilation activity, binds to two class B GPCRs, VPAC1 and VPAC2, to exert its functions in the CNS, vasculature, immune system and adrenal medulla (Harmar et al., 1998). In the immune system, VPAC2 is expressed on stimulated CD4 T cells, and binding of T cell-derived VIP to VPAC2 induces a shift toward the Th2 pathway (Delgado et al., 2004; Voice et al., 2004). In addition, VPAC2 is an essential regulator of the circadian pacemaker of the hypothalamic suprachiasmatic nuclei (Hughes et al., 2004). Chemicon′s VPAC2 membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression; thus, they are ideal HTS tools for screening of antagonists of VPAC2 interactions with PACAP. The membrane preparations exhibit a Kd of 0.9 nM for [125I]-PACAP27. With 5 µg/well VPAC2 Membrane Prep and 0.5 nM [125I]-PACAP27, a greater than 15-fold signal-to-background ratio was obtained.

Application

Radioligand binding assay, and GTPγS binding.


Biochem/physiol Actions

Protein Target: VPAC2 / VIP2

Features and Benefits

Inucbation Conditions
Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a nonbinding 96-well plate, and incubated for 1-2 h. Prior to filtration, a GF/C 96-well filter plate is coated with 0.33% polyethyleneimine for 30 min, then washed with 50mM HEPES, pH 7.4, 0.5% BSA. Binding reaction is transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The plate is dried and counted.

Binding buffer: 50 mM Hepes, pH 7.4, 5 mM MgCl2, 1 mM CaCl2, 0.2% BSA, filtered and stored at 4°C
Radioligand: [125I] PACAP27 (Perkin Elmer # NEX294)
Wash Buffer: 50 mM Hepes, pH 7.4, 500mM NaCl , 0.1% BSA, filtered and stored at 4°C.

One package contains enough membranes for at least 200 assays (units), where an unit is the amount of membrane that will yield greater than 15-fold signal:background with 125I-labeled PACAP27 at 0.5 nM.

Physical form

Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol and 1% BSA with no preservatives.
Packaging method: Membranes protein were adjusted to the indicated concentration in packaging buffer, rapidly frozen, and stored at -80°C.

Analysis Note

Signal:background and specific binding values obtained in a competition binding assay with 5ug/well of VPAC2 membrane prep:
10 µg/well5 µg/well
Signal:Background 25.5. 22.8
Specific Binding (cpm) 32913 27650


SPECIFICATIONS: 1 unit = 5 µg membrane preparation
Bmax: 17.3 pmol/mg
Kd: 0.9 nM

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Porovnat podobné položky

Zobrazit úplné porovnání

Zobrazit rozdíly

1 of 1

Tato položka
HTS043MHTS114MHTS001M
shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

shipped in

dry ice

technique(s)

ligand binding assay: suitable (GTPγS), radioligand binding assay (RLBA): suitable

technique(s)

ligand binding assay: suitable (GTPγS), radioligand binding assay (RLBA): suitable

technique(s)

ligand binding assay: suitable (GTPγS), radioligand binding assay (RLBA): suitable

technique(s)

ligand binding assay: suitable (GTPγS), radioligand binding assay (RLBA): suitable

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

UniProt accession no.

P41587

UniProt accession no.

P32241

UniProt accession no.

P41586

UniProt accession no.

P25024

biological source

human

biological source

human

biological source

human

biological source

human

recombinant

expressed in Chem-1 cells

recombinant

expressed in Chem-1 cells

recombinant

expressed in Chem-1 cells

recombinant

expressed in Chem-1 cells


Skladovací třída

12 - Non Combustible Liquids

wgk

WGK 2



Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů



Julia Voice et al.
Journal of immunology (Baltimore, Md. : 1950), 172(12), 7289-7296 (2004-06-10)
Vasoactive intestinal peptide and its G protein-coupled receptors, VPAC(1) and VPAC(2), regulate critical aspects of innate and adaptive immunity. T cell VPAC(2)Rs mediate changes in cytokine generation, which potently increase the Th2/Th1 ratio and consequently shift the effector responses toward
Alun T Hughes et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 24(14), 3522-3526 (2004-04-09)
VIP acting via the VPAC(2) receptor is implicated as a key signaling pathway in the maintenance and resetting of the hypothalamic suprachiasmatic nuclei (SCN) circadian pacemaker; circadian rhythms in SCN clock gene expression and wheel-running behavior are abolished in mice
Mario Delgado et al.
Pharmacological reviews, 56(2), 249-290 (2004-06-01)
First identified by Said and Mutt some 30 years ago, the vasoactive intestinal peptide (VIP) was originally isolated as a vasodilator peptide. Subsequently, its biochemistry was elucidated, and within the 1st decade, their signature features as a neuropeptide became consolidated.



Globální číslo obchodní položky

Skladová položkaGTIN
HTS079M04053252406928

Questions

Reviews

No rating value

Active Filters